bisoprolol and Infections, Coronavirus

bisoprolol has been researched along with Infections, Coronavirus in 1 studies

Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.

Research

Studies (1)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Cost of Intervention and Hospital Stay

Cost per patient calculated using cost of the intervention and costs of the hospital stay (NCT04348656)
Timeframe: Day 30

Death by Day 30

Occurrence of patient death at 30 days (NCT04348656)
Timeframe: Day 30

Development of Myocarditis

New diagnosis of myocarditis (NCT04348656)
Timeframe: Day 30

In-hospital Death

Occurrence of death while in hospital, censored at 90 days. Patients who were still in hospital at Day 30 were followed until Day 90 to capture in-hospital mortality. (NCT04348656)
Timeframe: Day 90

Length of Stay in Hospital

Number of days from randomization to death or hospital discharge. Patients still in hospital at Day 30 were followed until Day 90 to capture death or discharge from hospital. (NCT04348656)
Timeframe: Day 90

Length of Stay in Intensive Care Unit (ICU)

Number of days spent in the intensive care unit (ICU) over the 30-day period following randomization (NCT04348656)
Timeframe: Day 30

Need for Extracorporeal Membrane Oxygenation (ECMO)

Requirement for extracorporeal membrane oxygenation (ECMO) (NCT04348656)
Timeframe: Day 30

Need for Renal Replacement Therapy

Need for new renal replacement therapy (NCT04348656)
Timeframe: Day 30

Number of Participants Who Were Intubated or Died

Endpoint of the need for intubation or patient death (NCT04348656)
Timeframe: Day 30

Number of Participants With CCP Transfusion-associated Adverse Events (AE)

Number of participants experiencing CCP transfusion-associated adverse events (AE), as defined by the International Society of Blood Tranfusion (ISBT ) classification (NCT04348656)
Timeframe: Day 30

Number of Participants With Grade 3 and 4 Serious Adverse Events

Number of participants with Grade 3 and 4 (CTCAE v4.0) serious adverse events, and cumulative incidence of Grade 3 and 4 serious adverse events (using MedDRA AE terms) (NCT04348656)
Timeframe: Day 30

Number of Participants With Grade 3, 4, or 5 Serious Adverse Events

Number of Participants with Grade 3-5 (CTCAE v4.0) serious adverse events reported to Day 30 (NCT04348656)
Timeframe: Day 30

Patient Reported Outcome Using Change in EQ-5D-5L Score

Change in score on EQ-5D-5L instrument at Day 30 as compared to baseline. The EQ-5D-5L measures health-related quality of life in five dimensions, namely, mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Patients can report five level impairment, reflecting no, slight, moderate, severe, and extreme problems in each dimension. The range of possible values is -0.148 to 0.949, with a higher score reflecting a better outcome. For the change in score, a positive number indicates that the scores improved from baseline. (NCT04348656)
Timeframe: Baseline and Day 30

Patient Reported Outcome- Quality-adjusted Life Days

Quality-adjusted life days calculated using the EQ-5D-5L score. Quality-adjusted life days is a measure of how well a patient lives for how long. It combines the length of life and quality of life into one value. This is calculated by multiplying the health utility (derived from the EQ-5D-5L score) by the amount of time the patient is alive during the study period. A higher number is better. (NCT04348656)
Timeframe: Day 30

Time to In-hospital Death

Time to in-hospital death at 90 days. Patients who were still in hospital at Day 30 were followed until Day 90 to capture in-hospital mortality. (NCT04348656)
Timeframe: Day 90

Time to Intubation or In-hospital Death

Time in days from randomization to occurrence of intubation or death (NCT04348656)
Timeframe: Day 30

Ventilator-free Days by Day 30

Number of days off ventilator at 30 days (NCT04348656)
Timeframe: Day 30

Trials

1 trial available for bisoprolol and Infections, Coronavirus